Objectives-To identify and rank the factors that currently limit the use of thrombolytic treatment in patients admitted to hospital with acute myocardial infarction. Design-Weighted sampling study with retrospective data retrieval from clinical records. (Br Heart J 1995;74:224-228) 
Variation in thrombolytic use between districts showed a highly significant association with extent of earlier participation in multicentre trials of thrombolysis, but the ecological study design (in which the unit of analysis is a population rather than the individual patient) did not allow the influence of patient variables to be examined. 2 Patients entering clinical trials are a nonrandom sample of the clinical population that they are intended to represent, and the clinical characteristics of the latter are poorly defined. The limited use of thrombolytic treatment may reflect important differences between "typical" patients and trial patients, or a restrictive interpretation of indications and contraindications by clinicians. To have broad validity, analyses of clinical decision making must be based on properly constructed samples drawn from large populations. We have therefore examined the clinical characteristics and management of a random sample of all patients admitted to hospitals within the Trent region in whom acute myocardial infarction was the main diagnosis. The study was not designed to compare clinical management with a predefined protocol of "optimum treatment" or to examine treatment outcome. The aims were to analyse the determinants of thrombolytic use and to compare the patient population with the samples which have been included in the major thrombolytic trials. A common protocol was agreed by the European Secondary Prevention Study Group so that the data can ultimately be used to examine international variations in the management of acute myocardial infarction.
Patients and methods

STUDY POPULATION
Trent region has a population of 4-7 million (8-5% of the total United Kingdom population) and includes the counties of Derbyshire, Leicestershire, Lincolnshire, Nottinghamshire, and South Yorkshire. It is demographically representative of the United Kingdom and ischaemic heart disease mortality within the region is very close to the national average. Each year there are approximately 10 500 admissions to hospitals within the region in whom the main (discharge) diagnosis is acute myocardial infarction. Admission rates with this diagnosis in the 12 health districts range from 1-6 to 3-7 per 1000 population per year.
STUDY SAMPLE
The sampling frame consisted of patients in the population served by Trent Regional Health Authority who were discharged from hospital during February-April 1993 with acute myocardial infarction as the main discharge diagnosis. Patients who died in hospital were included. The sample size was chosen to give adequate precision (SE 2 5%) for a predicted thrombolysis rate of 50%. The sample requirement was divided between the 12 health districts in the region in proportion to the number of patients admitted with acute myocardial infarction during one month of the study time frame.
Listings of discharges for each district in the study time frame were provided by the Trent regional statistical department. The required number of patients (plus 20% to allow for non-availability of clinical records) was drawn from each district list by random sampling. For districts with more than one hospital receiving acute admissions, the sampling procedure ensured that the contribution from each hospital was proportional to its share of coronary admissions.
DATA RETRIEVAL
Records were reviewed on site about four months after the index admission. The notes were available for all but 12% of the sample, which were out of file for a range of reasons unlikely to cause significant bias. A standard data set was abstracted by one investigator and over 99% of data elements were available. The data included information on medical history, presenting features, and treatment received. The retrospective design was used to avoid possible bias which might arise if physicians were aware which RFatients were to be included in the study. No identifiers of patient, hospital, or district were entered into the study database; all analyses were performed on the entire regional sample. The feasibility of the design was confirmed in a pilot project in one hospital before the main study began.
STATISTICAL ANALYSIS
Associations between thrombolytic treatment and patient characteristics were estimated by the treatment odds ratio and its 95% confidence interval (CI) and tested by the x2 test. Stratified analyses used the Mantel Haenzsel procedure. The comparison category for the odds ratio is stated for each analysis.
Results
PATIENT CHARACTERISTICS
Data were collected on 420 patients with a mean age of 68 years (65 years for men and 74 years for women). Acute myocardial infarction had been diagnosed or suspected at admission in 89% of the sample; 53% of the total had been admitted to a coronary care unit. Delay from symptom onset to admission (fig) exceeded 12 h in 15% of patients. Table 1 gives the clinical characteristics of the study sample with the corresponding data from a summary of all large thrombolytic trials.' Because of its influence on United Kingdom practice, data for the second international study of infarct survival (ISIS-2)5 are also shown separately. In comparison with this random sample, patients included in the major thrombolytic trials were younger (P < 0.0001), more likely to have ST elevation on the admission electrocardiogram (P < 00001),-but less likely to have had previous myocardial infarction (P = 0.012). Women were under-represented in the trials (P < 0o0001). (table 2) . In contrast, there was no evidence that a more distant history of peptic ulceration or cardiopulmonary resuscitation during the index admission discouraged thrombolysis. Table 3 gives the influence of the initial electrocardiogram on treatment. Any electrocardiogram pattern other than ST elevation was associated with a highly significant reduction in thrombolytic use. This included bundle branch block, for which the treatment odds ratio was 0-18 (95% CI 007-0A44). The category other includes a normal initial electrocardiogram.
The effect of age on treatment was controlled for possible confounding by stroke or recent peptic ulcer history, or by later presentation among the elderly. After exclusion of patients with any of these factors, a negative association between increasing age and thrombolytic use was evident among patients with ST elevation on admission (table 4) . This was highly significant for patients aged >74 years. The association between patients' sex and their likelihood of receiving thrombolysis was confounded by age, and was nonsignificant after adjustment for this factor (P = 0.16).
PRINCIPAL FACTORS IN NON-USE OF THROMBOLYSIS
Of the 216 patients not given a thrombolytic drug, the time of symptom onset was greater than 12 h before admission or indeterminate in 63 (29%). In 114 (75%) of the remaining 153 there were clear diagnostic difficulties: acute myocardial infarction was not listed in the differential diagnosis at admission in 30 and there was no ST elevation in the initial electrocardiogram in 84 (although acute myocardial infarction was suspected). If these patients are excluded there remain only 12 with definite contraindications to thrombolysis and 27 without clear reason(s) for the withholding of thrombolytic treatment. If the latter (13% of all non-thrombolysed patients) had been treated, the overall thrombolysis rate would have risen only from 49% to 55%.
In any individual patient, more than one factor may contribute to the decision not to use thrombolysis. However, it is possible to infer from this sample a rank order of factors. Lack of a clear diagnosis at admission is the most important; the next is late presentation; and the least important is the presence of clear clinical contraindications to this form of treatment. Age is evidently an additional influential factor (table 4). Diagnostic difficulty was the main factor limiting the use of thrombolysis in the Trent sample. In 21% of patients not given thrombolytic treatment the diagnosis of acute myocardial infarction was not noted as a possibility at admission. Even when acute myocardial infarction was suspected, clinicians were clearly reluctant to give thrombolysis in the absence of ST elevation. This electrocardiogram feature may be transient or intermittent,'4 perhaps because of spontaneous reperfusion. It has been argued"5 that thrombolytic treatment should be given on the basis of strong clinical suspicion of acute myocardial infarction even without ST elevation, although the trials have not shown mortality benefit from thrombolytic treatment of patients with a normal electrocardiogram or ST depression.' Bundle branch block on the initial electrocardiogram was associated with a low likelihood of receiving a thrombolytic drug, even though such patients benefited from thrombolysis in the trials. A bundle branch block makes the electrocardiogram uninformative in the diagnosis of acute infarction; the trial patients with this electrocardiogram feature probably had particularly strong clinical evidence for the diagnosis.
DELAY FROM SYMPTOM ONSET TO ADMISSION
Delayed presentation reduces the population benefit to be had from thrombolysis in two ways: it increases the proportion of patients admitted too late to be treated and reduces the efficacy of treatment in the remainder.
In the trials, each hour of delay lessened the absolute reduction in 35 day mortality attributable to thrombolysis by 1 6 (SD 0-6) deaths per 1000 patients treated.' The balance of risk and benefit for thrombolytic treatment given beyond 12 h from symptom onset is debated and this is a widely adopted cut off for such treatment. Late presentation beyond this 12 h limit will exclude 15% of patients from thrombolysis.
SCOPE FOR WIDER USE OF THROMBOLYSIS
There is evidence of a consensus on the main clinical contraindications to thrombolytic treatment (table 2) , which were not a substantial limiting factor to the wider application of thrombolysis. There are several ways in which the public health impact of thrombolysis might be improved. First, better early diagnosis of myocardial infarction may be possible using serial electrocardiograms in the first few hours of admission to increase the likelihood of detecting ST segment elevation. The possible role of rapid cardiac enzyme assays is also being studied.'6 Second, better health education (particularly for those with known ischaemic heart disease) is needed to shorten admission delay times. '7 18 Third, the issue of thrombolysis in patients aged > 74 years must be resolved as this group comprises one third of all admissions with acute myocardial infarction in the United Kingdom.
